Diversity of antinuclear antibodies in progressive systemic sclerosis

Authors

  • Eng M. Tan MD,

    Professor and Head, Corresponding author
    1. Division of Rheumatic Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado and the Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
    • Rheumatology Division, University of Colorado Medical Center, 4200 East Ninth Street, Denver, Colorado 80220
    Search for more papers by this author
  • Gerald P. Rodnan MD,

    Professor and Head
    1. Division of Rheumatic Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado and the Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
    Search for more papers by this author
  • Ignacio Garcia MD,

    1. Division of Rheumatic Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado and the Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
    Search for more papers by this author
  • Yasuoki Moroi MD,

    1. Division of Rheumatic Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado and the Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
    Search for more papers by this author
  • M. J. Fritzler MD,

    Research Fellows
    1. Division of Rheumatic Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado and the Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
    Search for more papers by this author
  • Carol Peebles BS

    Senior Research Technician
    1. Division of Rheumatic Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado and the Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
    Search for more papers by this author

Abstract

Antinuclear antibodies wer demonstrated in the sera of 43 of 45 (96%) patients with progressive systemic sclerosis (22 of 24 with diffuse scleroderma and 21 of 21 with the CREST syndrome variant). This high percentage of positive reactions resulted from the use of a tissue culture substrate (Hep-2) to detect antinuclear antibodies by the indirect immunofluorescent method. Patterns of nuclear staining included diffuse fine speckles, large coarse speckles, nucleolar and centromere staining. When organ sections such as mouse kidney were used as substrate for the detection of antinuclear antibodies, nucleolar staining and centromere staining were the two patterns most frequently overlooked. Three types of antibodies appeared to be highly specific for scleroderma: antibody to Sc1-70 antigen, antibody to centromere, and antinucleolar antibody. The anti-centromere antibody appeared to be highly selective for the CREST variant of progressive systemic sclerosis.

Ancillary